苯二氮䓬受体激动剂治疗接受阿片受体激动剂治疗的苯二氮䓬依赖患者:随机对照试验BMX-BAR的研究方案
针对接受阿片受体激动剂治疗(OAT)合并苯二氮䓬依赖的患者,缺乏有效治疗方法。本研究为随机对照试验,计划纳入挪威六个门诊OAT诊所的108名参与者,比较26周苯二氮䓬稳定化治疗(每日地西泮15-30 mg或奥沙西泮50-100 mg)与20周逐渐减量方案,主要结局为第24周经观察尿检评估的非法苯二氮䓬使用。
要点
- 目标样本为挪威六个门诊OAT诊所的108名苯二氮䓬依赖患者。
- 干预为26周苯二氮䓬稳定化治疗,对照为20周逐渐减量,药物为地西泮或奥沙西泮。
- 主要结局为第24周观察尿检评估的非法苯二氮䓬使用。
核心结论
- 这是首个针对苯二氮䓬依赖的苯二氮䓬受体激动剂治疗的随机对照试验。
- 若干预被证实有效且安全,将被视为该患者群体标准治疗的选择之一。
研究设计与样本
- 随机对照试验,计划纳入108名来自挪威六个城市/郡门诊OAT诊所的参与者。
- 参与者随机接受26周苯二氮䓬稳定化治疗(每日地西泮15-30 mg或奥沙西泮50-100 mg)或20周逐渐减量(使用相同药物及等效初始剂量)。
- 所有参与者均可获得OAT治疗师的咨询及符合当前临床实践的心理社会随访。
主要发现
- 主要结局为第24周经观察尿检评估的非法苯二氮䓬使用。
- 次要结局包括精神健康症状、生活质量、认知表现、暴力风险、其他物质使用、治疗保留率及生活满意度。
- 还将评估治疗相关不良事件及干预的成本效益。
关键数值与推荐
- 主要纳入标准:苯二氮䓬依赖≥5年,过去一个月每周使用≥5天,且既往尝试过逐渐减量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment; however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches. A randomized controlled trial will be conducted to compare the efficacy and safety of stabilizing agonist treatment using prescribed benzodiazepines with standard treatment in reducing illicit benzodiazepine use. METHODS: The target sample is 108 participants at outpatient OAT clinics in six Norwegian cities/counties (Bergen/Vestland, Tønsberg/Vestfold, Skien/Telemark, Fredrikstad/Østfold, Tromsø/Troms, and Lillestrøm/Akershus). The main inclusion criteria are benzodiazepine dependence of ≥ 5 years, using ≥ 5 days a week during the last month, and previous attempts at tapering. Participants will be randomly assigned to receive either a 26-week benzodiazepine stabilizing treatment (15-30 mg diazepam or 50-100 mg oxazepam daily), or a 20-week tapering using the same medications and equivalent initial dosages. All participants will be given access to consultations from OAT therapists with psychosocial follow-up in accordance with current clinical practice. The primary outcome is the use of illicit benzodiazepines assessed by observed urinary tests at week 24. Secondary outcomes include mental health symptoms, quality of life, cognitive performance, violence risk, other substance use, treatment retention, and life satisfaction. Additionally, the study will assess treatment-related adverse events as well as the cost-effectiveness of the intervention. DISCUSSION: This is the first randomized controlled trial of benzodiazepine agonist treatment for benzodiazepine dependence. The research project will assess efficacy and safety of stabilizing treatment with prescribed benzodiazepines compared to benzodiazepine tapering and discontinuation regarding use of illicit benzodiazepines and accordingly well-being of patients with concurrent benzodiazepine and opioid dependence undergoing OAT. If the intervention is found to be efficacious and safe, it will be considered one of the options to standard treatment for this patient group. TRIAL REGISTRATION: EU trial number: EudraCT: 2021-004981-37. Registered on December 13, 2021.
引用
- Chalabianloo F, Fadnes LT, Assmus J, et al. Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR. Trials. 2025. PMID: 39748420. doi:10.1186/s13063-024-08692-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。